Atrophy

Viz.ai and UTMB Announce Collaboration to Accelerate Recruitment in the CHESS Study with Viz Subdural Solution

Retrieved on: 
木曜日, 5月 23, 2024
Software, Research, General Health, Pharmaceutical, Technology, Medical Devices, Infectious Diseases, Hospitals, Artificial Intelligence, Health Technology, Science, Neurology, Health, SDH, MPH, Bangladesh Technical Education Board, Patient, Chair, Randomized controlled trial, Viz, University, Ageing, Meta-analysis, Safety, FRCSC, DSM-IV codes, Systematic review, AI, Blood, MMAE, UTHealth School of Dentistry, Atrophy, University of Texas System, Workflow, Stroke, Professor, Brain, Chronic, CHESS, Triage, UTMB

In the CHESS trial, Viz.ai will notify investigators immediately when it detects a patient who has suspected SDH and meets the eligibility criteria for enrollment.

Key Points: 
  • In the CHESS trial, Viz.ai will notify investigators immediately when it detects a patient who has suspected SDH and meets the eligibility criteria for enrollment.
  • Study investigators can measure chronic bleeds4 and coordinate subject enrollment easily and securely through Viz.ai’s dynamic, mobile, HIPAA-compliant platform.
  • Management of chronic subdural hematoma with the subdural evacuating port system: Systematic review and meta-analysis.
  • https://pubmed.ncbi.nlm.nih.gov/33775320/
    4 Viz Subdural is currently available commercially for triage and notification.

Dry (Atrophic) Macular Degeneration Global Clinical Trials Review 2024: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status - ResearchAndMarkets.com

Retrieved on: 
金曜日, 5月 17, 2024
Health, Clinical Trials, E7, Clinical trial, Macular degeneration, Atrophy, G7, Trial, Ophthalmology, Pharmaceutical industry

The "Dry (Atrophic) Macular Degeneration - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dry (Atrophic) Macular Degeneration - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
  • The report provides an overview of Dry (Atrophic) Macular Degeneration Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Dry (Atrophic) Macular Degeneration.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024

Retrieved on: 
水曜日, 5月 8, 2024
MSD, PFS, FDA, Pfizer, MRNA, News, Atrophy, Weight loss, Doctor of Philosophy, Vaccine, University of Toronto, PFE, Medicinal chemistry, Medicine, Genome, Moderna, Diagnosis, AstraZeneca, Prevalence, GEJ, University, CPS, HER2, Food, OTC, IHC, Cachexia, Pneumococcal conjugate vaccine, Messenger, Quality of life, RSV, Patient, Facial muscles, Professor, Oncology, Trastuzumab, Research, Incidence, Fatigue, EPS, Neoplasm, MUSL, MRK, Tafamidis, Progression-free survival, PALM, PD-L1, COVID-19, Growth, Pharmaceutical industry

Cachexia is a medical condition known as ‘wasting syndrome’ that causes severe weight loss, muscle loss, and loss of body fats.

Key Points: 
  • Cachexia is a medical condition known as ‘wasting syndrome’ that causes severe weight loss, muscle loss, and loss of body fats.
  • The Cancer Cachexia market refers to the segment of the healthcare industry focused on addressing the multifaceted challenges associated with cachexia in cancer patients.
  • A report from Custom Market Insights projects that the global Cancer Cachexia Market is expected to record a CAGR of 5.1% from 2024 to 2033.
  • In 2024, the market size is projected to reach a valuation of USD 3.3 Billion.

Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology

Retrieved on: 
水曜日, 5月 8, 2024
Losmapimod, Fulcrum, Abdomen, NDA, The Lancet, Muscle weakness, REACH, Lancet Neurology, Disability, DUX4, Disease, Patient, FSHD, Face, Gene expression, Clinical trial, Therapy, File, Atrophy

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the publication of results from its Phase 2b clinical trial of losmapimod for the treatment of facioscapulopumeral muscular dystrophy (FSHD). The data are published in the peer-reviewed journal The Lancet Neurology.

Key Points: 
  • The data are published in the peer-reviewed journal The Lancet Neurology .
  • No serious adverse events related to the drug were reported, and there were no discontinuations of treatment due to adverse events.
  • In September 2023, Fulcrum announced the enrollment completion for the Phase 3 clinical trial evaluating losmapimod in patients with FSHD at sites in the United States, Canada, and Europe.
  • The clinical trial remains on track with topline data expected in Q4 2024.

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

Retrieved on: 
火曜日, 5月 7, 2024
Brain, ARCHER, Complement component 1q, CNV, Research, Microglia, Incidence, Patient, Eye, Pivotal, Vasculitis, Paratriathlon, Retinal pigment epithelium, Geographic atrophy, RPE, Atrophy, Annual general meeting, Synapse, ARVO, European Medicines Agency, Overalls, Visual acuity, Medical imaging

BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today presented new analyses of ANX007 from the Phase 2 ARCHER trial in geographic atrophy (GA), and new preclinical data on the role of C1q in the pathogenic elimination of photoreceptor synapses and their protection with C1q blockade in GA. ANX007 is a first-in-class, non-pegylated antigen-binding fragment (Fab) designed to block C1q and activation of the classical complement cascade locally in the eye with an intravitreal formulation, and is the first therapeutic candidate for the treatment of GA to receive Priority Medicine (PRIME) designation by the European Medicines Agency. The data were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting.

Key Points: 
  • The data were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting.
  • “We are pleased to present additional clinical data from the ARCHER trial that are the first to show preservation of both vision and relevant anatomical structures following ANX007 treatment,” said Douglas Love, president and chief executive officer of Annexon.
  • “Importantly, the statistically significant preservation of photoreceptor anatomy measured by ellipsoid zone change highlights protection of key retinal structures associated with vision.
  • These two registrational trials are designed to confirm the Phase 2 ARCHER findings of protection against vision loss and underscore the unique neuroprotective mechanism of action of ANX007 and its competitive differentiation in visual function.

OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit

Retrieved on: 
月曜日, 5月 6, 2024
Biotechnology, Health, General Health, Pharmaceutical, Optical, Health Technology, Other Science, Research, Genetics, Science, Clinical Trials, AMD, Patient, Cell, MM2, Geographic atrophy, MD, Doctor of Philosophy, OCT, Lineage, Paratriathlon, Degenerative disease, RPE, Atrophy, Therapy, Visual impairment, ELM

The meeting was jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute .

Key Points: 
  • The meeting was jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute .
  • The presentation, “OpRegen® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 24 Results from the Phase 1/2a Trial,” was presented by David Telander, MD, PhD , Retinal Consultants Medical Group, on behalf of Roche and Genentech , a member of the Roche Group.
  • RG6501 (OpRegen) is a suspension of human allogeneic retinal pigment epithelial (RPE) cells currently in development for the treatment of GA secondary to AMD.
  • OpRegen subretinal delivery has the potential to counteract RPE cell loss in areas of GA lesions by supporting retinal cell health and improving retinal structure and function.

NIRVANA WATER SCIENCES CORP. WELLNESS BEVERAGE NIRVANA SUPER™ NOW AVAILABLE IN 2,300 GNC STORES NATIONWIDE

Retrieved on: 
水曜日, 5月 8, 2024
Leucine, Nirvana, Inflammation, Facial muscles, Social media, GNC, HMB, NFL, Atrophy, Health, MD, Partnership, NBA, Pro, FACS, Diet, Dietary supplement

NEW YORK, May 8, 2024 /PRNewswire/ -- Nirvana Water Sciences Corp., an innovator in wellness products, today, in partnership with nutrition retailer GNC announced the nationwide availability of Nirvana Super Waters and Seltzers in 2,300 GNC stores across the U.S. This new partnership and distribution platform is the latest example of the wellness beverage line expanding at retail and marks a significant milestone for Nirvana Water Sciences Corp. as it continues its mission to provide great tasting, healthy products that help promote and protect lean muscle mass.

Key Points: 
  • NEW YORK, May 8, 2024 /PRNewswire/ -- Nirvana Water Sciences Corp., an innovator in wellness products, today, in partnership with nutrition retailer GNC announced the nationwide availability of Nirvana Super Waters and Seltzers in 2,300 GNC stores across the U.S.
  • HMB is naturally produced in your body when it metabolizes Leucine, an essential amino acid found in your diet.
  • The in-store and online GNC campaign notes Nirvana Super's key benefits such as energy efficacy and maintaining muscle health.
  • For more information about Nirvana Super and other products from Nirvana Water Sciences Corp., please visit www.feelsuper.com and join the conversation on social media at @NirvanaSuper on Instagram and Facebook .

Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
月曜日, 4月 15, 2024
Disability studies, Neuroinflammation, Oncology, Patient, Doctor of Pharmacy, ALS, Quality of life, Atrophy

DAZALS enrolled 249 patients, randomized 1:1:1 to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo daily for 24 weeks.

Key Points: 
  • DAZALS enrolled 249 patients, randomized 1:1:1 to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo daily for 24 weeks.
  • The study’s primary endpoint is change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R), which measures motor impairment and functional deterioration in patients with ALS.
  • “Dazucorilant showed great promise in an animal model of ALS – improving motor performance and reducing neuroinflammation and muscular atrophy.
  • Fully enrolling DAZALS is an important step toward understanding dazucorilant's potential for significantly improving outcomes for people living with this devastating disease.

Alzheon Announces First Patient Dosed in Long-Term Extension of APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate and Launches 52-Week Extension of Phase 2 Biomarker Trial in Patients with Early Alzheimer’s Disease

Retrieved on: 
火曜日, 4月 30, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Amyloid, MCI, APOE4, Risk, Safety, Cognition, MD, Doctor of Philosophy, ADAS, Disease, MB, Week, Atrophy, Patient, Master of Science, Alzheimer's disease, CSF, Genotype, Biomarker, Neurotoxicity, Cerebrospinal fluid, Plasma, Pharmaceutical industry

Early AD includes patients with mild cognitive impairment due to AD (MCI) and mild AD.

Key Points: 
  • Early AD includes patients with mild cognitive impairment due to AD (MCI) and mild AD.
  • ALZ-801/valiltramiprosate is an investigational oral disease-modifying therapy in Phase 3 development for the treatment of Early AD.
  • In mechanism of action studies, ALZ-801 fully blocked the formation of neurotoxic soluble beta amyloid oligomers at the Phase 3 clinical dose.
  • “Given these encouraging results, we are compelled to extend the trial for an additional year, bringing the treatment period to four years for these patients.

Supergut, the Leader in GLP-1 Functional Foods, Accelerates Its Unprecedented Retail Expansion With Newest Partner, GNC

Retrieved on: 
月曜日, 4月 29, 2024
General Health, Food, Beverage, Health, Retail, Fitness & Nutrition, Brain, Malnutrition, Digestion, Walmart, GNC, Bristol Farms, Nausea, Overweight, Diabetes, Insurance, Weight loss, Partnership, GLP-1, Atrophy, Prescription, Obesity, Food industry, Exercise, Science, Vomiting, Starch, Diarrhea, Metabolism, Constipation, Multimedia, Cardiovascular disease, Prediabetes, Immunity, Sleep, Injection, Dietary supplement

The partnership, which includes both in-store and online sales, accelerates Supergut’s unprecedented retail expansion over the past quarter.

Key Points: 
  • The partnership, which includes both in-store and online sales, accelerates Supergut’s unprecedented retail expansion over the past quarter.
  • In addition to this retail explosion, Supergut remains available on Supergut.com and Amazon .
  • “We’re excited to partner with GNC, which shares our values of scientific validation and customer education.
  • Approximately five million Americans take these drugs now, and up to 70 million Americans may use a GLP-1 by 2028 .